NCT06732596 Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
| NCT ID | NCT06732596 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Medical Center |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-10-30 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Opioid Use Disorder (OUD) * Within 30 days of intake at recruitment site (BMC OBAT) * Possession of a smartphone that has minimum requirements * English-speaking and reading * Willing to release electronic health record (EHR) data * Able to provide at least two alternate contacts who usually know how to get in touch with them * Currently prescribed buprenorphine from an outpatient clinic Exclusion Criteria: * Incarceration anticipated within 12 months of enrollment * Inability to comprehend the study protocol, defined as failing three times to answer correctly a set of questions during the consent process * Inability to use the ECA app (i.e., due to markedly limited visual or auditory acuity or motor function required to interact with the ECA)
Contact & Investigator
Karsten Lunze, MD MPH DrPH
PRINCIPAL INVESTIGATOR
Boston Medical Center
Frequently Asked Questions
Who can join the NCT06732596 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06732596 currently recruiting?
Yes, NCT06732596 is actively recruiting participants. Contact the research team at karsten.lunze@bmc.org for enrollment information.
Where is the NCT06732596 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06732596 clinical trial?
NCT06732596 is sponsored by Boston Medical Center. The principal investigator is Karsten Lunze, MD MPH DrPH at Boston Medical Center. The trial plans to enroll 100 participants.